Overview
- Discusses role of purinergic signalling in pathophysiological processes
- Overviews purinergic receptors and their modulators
- Highlights current perspectives and future challenges
Part of the book series: Topics in Medicinal Chemistry (TMC, volume 41)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (12 chapters)
-
Front Matter
Keywords
About this book
This book overviews purinergic receptors that are playing key roles in human and pathophysiological processes. The book elaborates on how selective P1 and P2 modulators have been developed as therapeutics for a variety of diseases. It also provides an overview of current perspectives in the design of purinergic receptor modulators and future challenges such as the availability of selective ligands for all receptor subtypes.
Divided into 12 chapters, this comprehensive volume also offers a multidisciplinary perspective on the historical evolution, starting with a chapter devoted to the roots and early discoveries of adenosine and its receptors, followed by a twenty-year retrospective on the synthesis, properties, and functional potential of adenosine receptor ligands, probes, and functional conjugates. In the next chapters, experts in the field delve into topics such as the therapeutic potential of adenosine receptor ligands in wound healing and fibrosis, the therapeutic benefits of A2A receptor antagonists, the A2B adenosine receptor as a target for brain ischemia or demyelination, the development and latest advancements in clinical trials of A3 adenosine receptor ligands. Other chapters describe bifunctional tools to study adenosine receptors, allosteric modulators of adenosine receptors, and new computational approaches to inspect adenosine receptor-ligand recognition processes. Furthermore, the book discusses the role of P2X4 receptors in immunity and inflammation. The final chapters illustrate CD73 inhibitors as antitumor agents, and bacterial ectonucleotidases as underexplored antibacterial drug targets.
This book is a valuable resource for scholars working in the field of medicinal chemistry, as well as researchers in the industry, providing readers with a comprehensive understanding of adenosine receptor biology and its therapeutic potential.
Editors and Affiliations
About the editors
Claudiu T. Supuran is a Full Professor of Medicinal Chemistry at Dipartimento Neurofarba, Universita` degli Studi di Firenze, Sezione di Scienze Farmaceutiche e Nutraceutiche, Florence, Italy. He received his BSc in Chemistry from the Polytechnic University of Bucharest, Romania (1987), and Ph. D. in Chemistry at the same university in 1991. His research interests focus on drug development against Carbonic anhydrases and other enzymes. He has published 2000+ research articles on enzyme inhibitors/activators, being one of the most cited medicinal chemists worldwide. His research is also focused on metalloenzymes cloning, characterization and inhiibtion studies, carbonic anhydrases, proteases, heterocyclic chemistry, chemistry of sulfonamides, sulfamates and sulfamides, X-ray crystallography ofmetallo-enzymes, biologically active organo-element derivatives, quantitative structure-activity relationship (QSAR) studies, metal-based drugs, cyclooxygenases inhibitors, serine proteases, matrix metalloproteinases, bacterial proteases, antivirals, antitumor drugs, ophthalmologic drugs and amino acid derivatives. One sulfonamide carbonic anhydrase inhibitor discovered in his laboratory, SLC-0111, completed Phase I clinical trials as antitumor/antimetastatic agent in 2014 and is presently in Phase Ib/II clinical trials in North America, being developed for the treatment of advanced, metastatic solid tumors.
Bibliographic Information
Book Title: Purinergic Receptors and their Modulators
Editors: Vittoria Colotta, Claudiu T. Supuran
Series Title: Topics in Medicinal Chemistry
DOI: https://doi.org/10.1007/978-3-031-39725-7
Publisher: Springer Cham
eBook Packages: Chemistry and Materials Science, Chemistry and Material Science (R0)
Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023
Hardcover ISBN: 978-3-031-39724-0Published: 29 September 2023
Softcover ISBN: 978-3-031-39727-1Due: 30 October 2023
eBook ISBN: 978-3-031-39725-7Published: 28 September 2023
Series ISSN: 1862-2461
Series E-ISSN: 1862-247X
Edition Number: 1
Number of Pages: X, 354
Topics: Medicinal Chemistry, Biochemistry, general, Life Sciences, general